HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

KEYMED BIO-B

38.650

-9.350-19.48%

Volume:7.55M

Turnover:301.97M

Market Cap:10.81B

PE:-18.54

High:43.000

Open:43.000

Low:37.350

Close:48.000

Loading ...

Overview Company News Filings

the Phase Iii Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

THOMSON REUTERS

Keymed Biosciences Inc. (HKG:2162) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Simply Wall St.

Stock Track | KEYMED BIO-B Soars 5.17% Following Strong 2024 Annual Results and Pipeline Advancements

Stock Track | Keymed Biosciences Soars 5.17% Following Strong 2024 Annual Results and Pipeline Progress

Press Release: Keymed Biosciences Announces Annual Results of 2024

BRIEF-Keymed Biosciences Posts FY Revenue Of RMB428.1 Million

KeyMed Biosciences FY Revenue RMB 36 Million

THOMSON REUTERS

KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic Rhinitis

THOMSON REUTERS

KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic Rhinitis

THOMSON REUTERS

Keymed Biosciences Get China Nod for Supplementary NDA of Rhinitis Drug

MT Newswires Live

KeyMed Biosciences - Nmpa Approved Snda of Stapokibart for Treatment of Seasonal Allergic Rhinitis

THOMSON REUTERS

Keymed-Innocare JV Signs Commercial License Deal for Anti-Tumor Drug

MT Newswires Live

InnoCare Pharma Unit Outsources Manufacturing, Commercialization License for Tumor Drug

MT Newswires Live

InnoCare and KeyMed Jointly Announce the License Agreement With Prolium for Cd20xcd3 Bispecific Antibody Icp-B02

THOMSON REUTERS

BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355

KeyMed Biosciences Inc - Chengdu KeyMed and Beijing InnoCare Will Receive $17.5 Mln, and Additional Payments up to US$502.5 Mln

THOMSON REUTERS

KeyMed Biosciences - License Agreement With Prolium for Development and Commercialization of Cm355

THOMSON REUTERS

Keymed Biosciences' Unit Signs License Deal for Drug's Commercialization

MT Newswires Live

Press Release: Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs

KeyMed Biosciences Inc - Group to Receive Upfront and Near-Term Payment of US$30 Mln & Stake of Timberlyne Therapeutics

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02162/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02162","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02162\",,,,,undefined,":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"KEYMED BIO-B","latestPrice":38.65,"timestamp":1744013346017,"preClose":48,"halted":0,"volume":7552000,"delay":0,"floatShares":279735566,"shares":279735566,"eps":-2.0848962533850184,"marketStatus":"Closed","change":-9.35,"latestTime":"04-07 16:09:06","open":43,"high":43,"low":37.35,"amount":301972737,"amplitude":0.117708,"askPrice":38.7,"askSize":22000,"bidPrice":38.65,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":-2.0848962533850184,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744075800000},"marketStatusCode":5,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":48,"openAndCloseTimeList":[[1743989400000,1743998400000],[1744002000000,1744012800000]],"volumeRatio":2.408559,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02162\",,,,,undefined,":{"symbol":"02162","floatShares":279735566,"roa":"-10.23%","roe":"-18.85%","lyrEps":-2.084896,"volumeRatio":2.408559,"shares":279735566,"dividePrice":0,"high":43,"amplitude":0.117708,"preClose":48,"low":37.35,"week52Low":26.6,"pbRate":"4.12","psRate":"23.83","week52High":49.6,"institutionHeld":0,"latestPrice":38.65,"committee":-0.660377,"eps":-2.0848962533850184,"divideRate":0,"volume":7552000,"delay":0,"ttmEps":-2.0848962533850184,"open":43,"prevYearClose":30.9,"prevWeekClose":48,"prevMonthClose":44.4,"prevQuarterClose":44.4,"fiveDayClose":45,"twentyDayClose":36.7,"sixtyDayClose":29},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02162\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525771311","title":"the Phase Iii Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2525771311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525771311?lang=en_us&edition=fundamental","pubTime":"2025-04-05 22:17","pubTimestamp":1743862632,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250405:nTUA7MNXR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1583","02162","BK1587"],"gpt_icon":0},{"id":"2522132511","title":"Keymed Biosciences Inc. (HKG:2162) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522132511","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522132511?lang=en_us&edition=fundamental","pubTime":"2025-03-28 09:26","pubTimestamp":1743125197,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. ( HKG:2162 ) just released its latest full-year results and things are looking bullish. Revenue...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-inc-hkg2162-just-reported-full-year-earni","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02162"],"gpt_icon":0},{"id":"1155758065","title":"Stock Track | KEYMED BIO-B Soars 5.17% Following Strong 2024 Annual Results and Pipeline Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=1155758065","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155758065?lang=en_us&edition=fundamental","pubTime":"2025-03-27 10:24","pubTimestamp":1743042276,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B  shares are soaring 5.17% in Thursday's trading session, following the company's announcement of its annual results for 2024 and updates on its pipeline products. The biotechnology firm's strong performance and significant advancements in its drug development programs have evidently boosted investor confidence.One of the key highlights from the annual results is the success of Keymed's lead product, Stapokibart , an IL-4Rα antibody. The company reported that Stapokibart received thr","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02162"],"gpt_icon":0},{"id":"1116736863","title":"Stock Track | Keymed Biosciences Soars 5.17% Following Strong 2024 Annual Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1116736863","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116736863?lang=en_us&edition=fundamental","pubTime":"2025-03-27 10:24","pubTimestamp":1743042275,"startTime":"0","endTime":"0","summary":"Shares of Keymed Biosciences  are soaring 5.17% in Thursday's trading session, following the release of the company's impressive 2024 annual results and pipeline updates. The biotechnology firm's stock price surge reflects investor optimism about its strong product performance and advancement in clinical trials across multiple therapeutic areas.A key highlight from the annual report is the successful launch and sales performance of Stapokibart , an IL-4Rα antibody. The drug, approved for multipl","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Keymed Biosciences Soars 5.17% Following Strong 2024 Annual Results and Pipeline Progress","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02162"],"gpt_icon":0},{"id":"2522138618","title":"Press Release: Keymed Biosciences Announces Annual Results of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2522138618","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522138618?lang=en_us&edition=fundamental","pubTime":"2025-03-26 23:09","pubTimestamp":1743001740,"startTime":"0","endTime":"0","summary":"CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc.  announced its annual results of 2024, along with a corporate update.Three new drug applications of Stapokibart for the treatment of moderate-to-severe atopic dermatitis  in adults, chronic rhinosinusitis with nasal polyposis  and seasonal allergic rhinitis have been approved by the NMPA. By the end of 2024, Stapokibart resisted strong sales and recorded revenue of approximately RMB40 million within three and a half months.-- In September 2024, the new drug application of Stapokibart injection for. the treatment of moderate-to-severe atopic dermatitis in adults was. approved by the NMPA. The phase III clinical study results indicated that. at week 52, the rates of achieving EASI-75 for the Stapokibart group and. EASI-90 response rates were 77.1% and 65.6%, respectively. The rates of. achieving an IGA score of 0 or 1 point with a reduction of >= 2 points. from baseline were 67.3% and 64.2%, respectiv","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAR","02162","ASH","IE0002270589.USD","IE00B19Z3581.USD","BK4588","BK1587","IE00BSNM7G36.USD","BK4196","LU0058720904.USD","LU1261432733.SGD","BK1574","LU1059921491.USD","LU2463526074.USD","BK4585","BK4109","LU0289739699.SGD","IE00B19Z3B42.SGD","BK1583","BK1161","BK4135","CI","LU0868494617.USD"],"gpt_icon":0},{"id":"2521577729","title":"BRIEF-Keymed Biosciences Posts FY Revenue Of RMB428.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521577729","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521577729?lang=en_us&edition=fundamental","pubTime":"2025-03-24 21:11","pubTimestamp":1742821885,"startTime":"0","endTime":"0","summary":"BRIEF-Keymed Biosciences Posts FY Revenue Of RMB428.1 Million March 24 (Reuters) - Keymed Biosciences Inc 2162.HK:FY REVENUE RMB 428.1 MILLION FY NET INCOME ATTRIBUTABLE RMB -480.6 MILLIONFurther company coverage: 2162.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL5N3Q711H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"gpt_icon":0},{"id":"2521262947","title":"KeyMed Biosciences FY Revenue RMB 36 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521262947","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521262947?lang=en_us&edition=fundamental","pubTime":"2025-03-24 21:05","pubTimestamp":1742821523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nPLXBFB5A4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1161","BK1574","BK1583","02162"],"gpt_icon":0},{"id":"2509334704","title":"KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic Rhinitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2509334704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509334704?lang=en_us&edition=fundamental","pubTime":"2025-02-08 09:50","pubTimestamp":1738979439,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250208:nTUA2RCGNT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","02162","BK1574","BK1587"],"gpt_icon":0},{"id":"2509709177","title":"KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic Rhinitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2509709177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509709177?lang=en_us&edition=fundamental","pubTime":"2025-02-08 09:14","pubTimestamp":1738977256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250208:nTUA3WCVHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02162","BK1587","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2509713532","title":"Keymed Biosciences Get China Nod for Supplementary NDA of Rhinitis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2509713532","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509713532?lang=en_us&edition=fundamental","pubTime":"2025-02-07 18:17","pubTimestamp":1738923423,"startTime":"0","endTime":"0","summary":"Keymed Biosciences (HKG:2162) received approval from China's National Medical Products Administration for its supplemental new drug application (sNDA) of Stapokibart.Stapokibart is used for the treatment of seasonal allergic rhinitis, a Friday bourse filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02162","BK1583","BK1587","BK1574","BK1161"],"gpt_icon":0},{"id":"2509799271","title":"KeyMed Biosciences - Nmpa Approved Snda of Stapokibart for Treatment of Seasonal Allergic Rhinitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2509799271","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509799271?lang=en_us&edition=fundamental","pubTime":"2025-02-07 16:30","pubTimestamp":1738917036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OY10D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02162","BK1574","BK1583","BK1587","BK1161"],"gpt_icon":0},{"id":"2505322568","title":"Keymed-Innocare JV Signs Commercial License Deal for Anti-Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505322568","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505322568?lang=en_us&edition=fundamental","pubTime":"2025-01-21 19:33","pubTimestamp":1737459180,"startTime":"0","endTime":"0","summary":"A joint venture with Keymed Biosciences  and InnoCare  unit Beijing InnoCare Pharma Tech signed a license agreement with Prolium to develop the CM355 drug for tumors.Under the license deal, Prolium will obtain exclusive rights to develop, register, manufacture, and commercialize the drug outside of Asia, according to a Monday filing with the Hong Kong Exchange.Keymed's Chengdu unit and Innocare Unit Beijing InnoCare will be entitled to upfront and near-term payments of $17.5 million, up to $502.5 million in additional payments, and tiered royalties on net sales from Prolium based on their respective interests in the Beijing Tiannuojiancheng Pharma Tech joint venture.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688428","09969","BK1161","BK1574","BK1587","BK0239","02162","BK1583"],"gpt_icon":0},{"id":"2505210109","title":"InnoCare Pharma Unit Outsources Manufacturing, Commercialization License for Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505210109","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505210109?lang=en_us&edition=fundamental","pubTime":"2025-01-21 16:38","pubTimestamp":1737448736,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  unit Beijing InnoCare Pharma Tech and certain other parties have entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02, a Monday Hong Kong bourse filing said.The contract grants Prolium the exclusive right to develop, register, manufacture, and commercialize ICP-B02 globally in non-oncology fields and in global oncology fields outside of Asia.ICP-B02 is designed to redirect and activate T-cells to eliminate tumor cells through T-cell Dependent Cellular Cytotoxicity and is undergoing clinical trials to assess its safety and efficacy.Beijing InnoCare Pharma Tech and Keymed Biosciences'  unit Keymed Biosciences  each own 50% rights in ICP-B02, with future revenue to be shared equally between the parties.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1587","BK1574","09969","688428","5I4.SI","BK0239","BK6512","02162","BK1161","BK6004","BK1583"],"gpt_icon":0},{"id":"2504386408","title":"InnoCare and KeyMed Jointly Announce the License Agreement With Prolium for Cd20xcd3 Bispecific Antibody Icp-B02","url":"https://stock-news.laohu8.com/highlight/detail?id=2504386408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504386408?lang=en_us&edition=fundamental","pubTime":"2025-01-20 18:36","pubTimestamp":1737369360,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250120:nTUA9M1W51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","688428","BK1574","BK0239","02162","BK1583","BK1587"],"gpt_icon":0},{"id":"2504477932","title":"BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355","url":"https://stock-news.laohu8.com/highlight/detail?id=2504477932","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504477932?lang=en_us&edition=fundamental","pubTime":"2025-01-20 18:12","pubTimestamp":1737367969,"startTime":"0","endTime":"0","summary":"BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355Jan 20  - Keymed Biosciences 2162.HK:LICENSE AGREEMENT WITH PROLIUM FOR DEVELOPMENT AND COMMERCIALIZATION OF CM355CHENGDU KEYMED AND BEIJING INNOCARE WILL RECEIVE $17.5 MILLION,  AND ADDITIONAL PAYMENTS UP TO US$502.5 MILLIONFurther company coverage: 2162.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250120:nFWN3OE0AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1161","02162","BK1583","BK1574"],"gpt_icon":0},{"id":"2504472206","title":"KeyMed Biosciences Inc -  Chengdu KeyMed and Beijing InnoCare Will Receive $17.5 Mln,  and Additional Payments up to US$502.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2504472206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504472206?lang=en_us&edition=fundamental","pubTime":"2025-01-20 18:00","pubTimestamp":1737367248,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250120:nFWN3OE0AO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","02162","BK1587","BK1583","BK1161"],"gpt_icon":0},{"id":"2504472205","title":"KeyMed Biosciences  - License Agreement With Prolium for Development and Commercialization of Cm355","url":"https://stock-news.laohu8.com/highlight/detail?id=2504472205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504472205?lang=en_us&edition=fundamental","pubTime":"2025-01-20 18:00","pubTimestamp":1737367248,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250120:nFWN3OE0AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02162","BK1161","BK1587","BK1574","BK1583"],"gpt_icon":0},{"id":"2502292883","title":"Keymed Biosciences' Unit Signs License Deal for Drug's Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2502292883","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502292883?lang=en_us&edition=fundamental","pubTime":"2025-01-10 13:21","pubTimestamp":1736486489,"startTime":"0","endTime":"0","summary":"Keymed Biosciences'  unit, Keymed Biosciences , and Timberlyne Therapeutics signed an exclusive out-license agreement for the exclusive right to develop, manufacture, and commercialize CM313 globally, excluding mainland China, Hong Kong, Macau, and Taiwan, according to a Friday filing with the Hong Kong bourse.The group will receive an upfront payment of $30 million and an equity stake in Timberlyne Therapeutics. It may earn up to $337.5 million in milestone payments based on sales and development goals, plus tiered royalties from Timberlyne's net sales.CM313 is a specialized antibody that targets CD38, a protein linked to various diseases. It works by triggering the immune system to destroy harmful cells and has shown strong results in treating conditions like Immune Thrombocytopenia, Lupus, advanced Multiple Myeloma, and autoimmune diseases, the filing noted.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1587","BK1583","BK1161","BK1574","02162"],"gpt_icon":0},{"id":"2502707900","title":"Press Release: Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs","url":"https://stock-news.laohu8.com/highlight/detail?id=2502707900","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502707900?lang=en_us&edition=fundamental","pubTime":"2025-01-10 09:30","pubTimestamp":1736472600,"startTime":"0","endTime":"0","summary":"Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs. Mountainfield Venture Partners, a biopharmaceutical company creation firm, partners with Keymed Biosciences to form Timberlyne Therapeutics, accessing global development and commercial rights outside of greater China for CM313. Financing co-led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners. Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for high unmet medical needs. Timberlyne's lead program is CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, which is highly expressed on plasma cells, NK cells, and other immune cells, CM313 modulates multiple immune cell types leading to both rapid and durab","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4139","02162","BK1574","BK1587","BK1583","LENZ"],"gpt_icon":0},{"id":"2502745079","title":"KeyMed Biosciences Inc - Group to Receive Upfront and Near-Term Payment of US$30 Mln & Stake of Timberlyne Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2502745079","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502745079?lang=en_us&edition=fundamental","pubTime":"2025-01-10 08:01","pubTimestamp":1736467270,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nFWN3O50N8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02162","BK1583","BK1587","BK1574","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02162\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"02162","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post Market","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-27","symbol":"02162","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724722200000,"name":null,"time":"Post Market","dateTimestamp":1724688000000,"actualEps":null},{"date":"2024-03-26","symbol":"02162","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711416600000,"name":null,"time":"","dateTimestamp":1711382400000,"actualEps":null},{"date":"2023-08-24","symbol":"02162","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692840600000,"name":null,"time":"","dateTimestamp":1692806400000,"actualEps":null},{"date":"2023-03-17","symbol":"02162","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1679016600000,"name":null,"time":"","dateTimestamp":1678982400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02162\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02162\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1743436800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02162\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02162","date":"2025-04-03","current":-24.037662,"percent":0.461039,"low":-75.021907,"twenty":-47.928354,"median":-22.787126,"eighty":-2.100685,"high":-0.918807,"avg":-25.308102,"sd":19.953404,"marketCap":13228779168},"quantilePoints":[{"date":"2021-07-09","current":-19.162927,"twenty":-18.949964,"median":-16.76249,"eighty":-14.711698,"marketCap":18807126980},{"date":"2021-07-16","current":-18.776742,"twenty":-19.237066,"median":-18.807989,"eighty":-17.152246,"marketCap":18427732488},{"date":"2021-07-23","current":-17.618697,"twenty":-19.184823,"median":-18.776246,"eighty":-18.022613,"marketCap":17289549010},{"date":"2021-07-30","current":-17.657215,"twenty":-19.136205,"median":-18.698458,"eighty":-16.553895,"marketCap":17385565426},{"date":"2021-08-06","current":-18.597059,"twenty":-19.136205,"median":-18.68783,"eighty":-17.309281,"marketCap":18266732459},{"date":"2021-08-13","current":-17.775416,"twenty":-19.159423,"median":-18.698458,"eighty":-17.567372,"marketCap":17483472875},{"date":"2021-08-20","current":-15.116391,"twenty":-19.133869,"median":-18.605125,"eighty":-17.508281,"marketCap":14825984998},{"date":"2021-08-27","current":-14.325953,"twenty":-19.029178,"median":-18.069277,"eighty":-15.500902,"marketCap":14112659304},{"date":"2021-09-03","current":-2.665037,"twenty":-18.872675,"median":-17.808518,"eighty":-14.711698,"marketCap":14154619639},{"date":"2021-09-10","current":-2.889349,"twenty":-18.789241,"median":-17.637409,"eighty":-13.902099,"marketCap":15385456130},{"date":"2021-09-17","current":-2.734582,"twenty":-18.776146,"median":-17.505299,"eighty":-2.874329,"marketCap":14518275875},{"date":"2021-09-24","current":-2.75965,"twenty":-18.761327,"median":-16.432963,"eighty":-2.778159,"marketCap":14658143658},{"date":"2021-09-30","current":-2.700581,"twenty":-18.731857,"median":-15.436816,"eighty":-2.745012,"marketCap":14392394870},{"date":"2021-10-08","current":-2.561601,"twenty":-18.700103,"median":-14.765165,"eighty":-2.70068,"marketCap":13651095620},{"date":"2021-10-15","current":-2.334285,"twenty":-18.698458,"median":-14.703758,"eighty":-2.689311,"marketCap":12448232687},{"date":"2021-10-22","current":-2.143171,"twenty":-18.677203,"median":-14.267689,"eighty":-2.634146,"marketCap":11511118540},{"date":"2021-10-29","current":-2.088441,"twenty":-18.61319,"median":-3.090995,"eighty":-2.598807,"marketCap":11189422640},{"date":"2021-11-05","current":-2.025061,"twenty":-18.597059,"median":-2.870574,"eighty":-2.541082,"marketCap":10867726739},{"date":"2021-11-12","current":-1.910328,"twenty":-18.29189,"median":-2.805921,"eighty":-2.289961,"marketCap":10294268828},{"date":"2021-11-19","current":-2.26913,"twenty":-18.069277,"median":-2.754866,"eighty":-2.242018,"marketCap":12210457455},{"date":"2021-11-26","current":-2.611393,"twenty":-17.907229,"median":-2.734582,"eighty":-2.238418,"marketCap":14056712191},{"date":"2021-12-03","current":-2.53136,"twenty":-17.841621,"median":-2.70083,"eighty":-2.242018,"marketCap":13651095620},{"date":"2021-12-10","current":-2.234466,"twenty":-17.775416,"median":-2.693016,"eighty":-2.242018,"marketCap":12070589672},{"date":"2021-12-17","current":-1.969142,"twenty":-17.657215,"median":-2.681903,"eighty":-2.198856,"marketCap":10629951508},{"date":"2021-12-24","current":-1.801599,"twenty":-17.637409,"median":-2.665037,"eighty":-2.113389,"marketCap":9734797696},{"date":"2021-12-31","current":-1.782191,"twenty":-17.622439,"median":-2.625661,"eighty":-2.0876,"marketCap":9650877027},{"date":"2022-01-07","current":-1.534896,"twenty":-1.704098,"median":-1.627879,"eighty":-1.527695,"marketCap":8280172753},{"date":"2022-01-14","current":-1.453948,"twenty":-1.669883,"median":-1.556361,"eighty":-1.51183,"marketCap":7860569404},{"date":"2022-01-21","current":-1.391259,"twenty":-1.63569,"median":-1.534896,"eighty":-1.46926,"marketCap":7538873503},{"date":"2022-01-28","current":-1.304246,"twenty":-1.623821,"median":-1.510565,"eighty":-1.374247,"marketCap":7049336263},{"date":"2022-02-04","current":-1.364435,"twenty":-1.621116,"median":-1.501786,"eighty":-1.358567,"marketCap":7371032164},{"date":"2022-02-11","current":-1.377188,"twenty":-1.560501,"median":-1.453948,"eighty":-1.36091,"marketCap":7454952833},{"date":"2022-02-18","current":-1.517016,"twenty":-1.552222,"median":-1.451036,"eighty":-1.364435,"marketCap":8252199197},{"date":"2022-02-25","current":-1.400429,"twenty":-1.54809,"median":-1.441856,"eighty":-1.364435,"marketCap":7636780951},{"date":"2022-03-04","current":-1.507578,"twenty":-1.539833,"median":-1.451036,"eighty":-1.369844,"marketCap":8224225640},{"date":"2022-03-11","current":-1.389171,"twenty":-1.534896,"median":-1.445096,"eighty":-1.369844,"marketCap":7566847060},{"date":"2022-03-18","current":-0.979665,"twenty":-1.532907,"median":-1.435643,"eighty":-1.358567,"marketCap":5314975754},{"date":"2022-03-25","current":-0.982717,"twenty":-1.528918,"median":-1.429599,"eighty":-1.332001,"marketCap":5331759887},{"date":"2022-04-01","current":-1.3179,"twenty":-1.517016,"median":-1.397825,"eighty":-1.261154,"marketCap":6308037013},{"date":"2022-04-08","current":-1.477979,"twenty":-1.516918,"median":-1.419667,"eighty":-1.295628,"marketCap":7077309819},{"date":"2022-04-14","current":-1.480428,"twenty":-1.512775,"median":-1.420186,"eighty":-1.312438,"marketCap":7077309819},{"date":"2022-04-22","current":-1.392349,"twenty":-1.509049,"median":-1.415098,"eighty":-1.309996,"marketCap":6531825466},{"date":"2022-04-29","current":-1.31153,"twenty":-1.506241,"median":-1.395221,"eighty":-1.308764,"marketCap":6461891574},{"date":"2022-05-06","current":-1.205149,"twenty":-1.503255,"median":-1.392349,"eighty":-1.271328,"marketCap":5888433664},{"date":"2022-05-13","current":-1.186298,"twenty":-1.499337,"median":-1.389171,"eighty":-1.220758,"marketCap":5692618768},{"date":"2022-05-20","current":-1.31073,"twenty":-1.49254,"median":-1.384218,"eighty":-1.235206,"marketCap":6377970904},{"date":"2022-05-27","current":-1.311868,"twenty":-1.481525,"median":-1.369844,"eighty":-1.235206,"marketCap":6377970904},{"date":"2022-06-02","current":-1.38785,"twenty":-1.480647,"median":-1.369844,"eighty":-1.235548,"marketCap":6783587475},{"date":"2022-06-10","current":-1.731429,"twenty":-1.500317,"median":-1.384022,"eighty":-1.237922,"marketCap":8406053758},{"date":"2022-06-17","current":-1.695836,"twenty":-1.516918,"median":-1.384891,"eighty":-1.242218,"marketCap":8224225640},{"date":"2022-06-24","current":-2.010847,"twenty":-1.534951,"median":-1.390215,"eighty":-1.257553,"marketCap":9790744810},{"date":"2022-06-30","current":-1.899212,"twenty":-1.549743,"median":-1.393274,"eighty":-1.262321,"marketCap":9231273678},{"date":"2022-07-08","current":-1.880011,"twenty":-1.623821,"median":-1.400429,"eighty":-1.269129,"marketCap":9147353008},{"date":"2022-07-15","current":-1.851172,"twenty":-1.698941,"median":-1.419667,"eighty":-1.291807,"marketCap":8923564555},{"date":"2022-07-22","current":-1.855758,"twenty":-1.725957,"median":-1.429599,"eighty":-1.304535,"marketCap":8951538112},{"date":"2022-07-29","current":-1.766614,"twenty":-1.744535,"median":-1.433618,"eighty":-1.306043,"marketCap":8531934763},{"date":"2022-08-05","current":-1.817581,"twenty":-1.744535,"median":-1.441856,"eighty":-1.30743,"marketCap":8755723215},{"date":"2022-08-12","current":-1.8644,"twenty":-1.770378,"median":-1.451036,"eighty":-1.309546,"marketCap":8993498446},{"date":"2022-08-19","current":-1.851032,"twenty":-1.788753,"median":-1.464163,"eighty":-1.31121,"marketCap":8839643885},{"date":"2022-08-26","current":-2.102,"twenty":-1.805605,"median":-1.478724,"eighty":-1.311733,"marketCap":9958586149},{"date":"2022-09-02","current":-34.599164,"twenty":-1.828013,"median":-1.480428,"eighty":-1.315487,"marketCap":9972572927},{"date":"2022-09-09","current":-36.0466,"twenty":-1.851951,"median":-1.495938,"eighty":-1.318745,"marketCap":10350215942},{"date":"2022-09-16","current":-37.90693,"twenty":-1.859627,"median":-1.505907,"eighty":-1.321265,"marketCap":10783806069},{"date":"2022-09-23","current":-33.886683,"twenty":-1.87468,"median":-1.516894,"eighty":-1.325171,"marketCap":9455062130},{"date":"2022-09-30","current":-35.623246,"twenty":-1.900823,"median":-1.530912,"eighty":-1.328777,"marketCap":9958586149},{"date":"2022-10-07","current":-36.67604,"twenty":-1.924198,"median":-1.535033,"eighty":-1.334346,"marketCap":10252308493},{"date":"2022-10-14","current":-37.625514,"twenty":-1.970352,"median":-1.54809,"eighty":-1.344356,"marketCap":10406163055},{"date":"2022-10-21","current":-38.597844,"twenty":-2.014364,"median":-1.585508,"eighty":-1.346932,"marketCap":10601977951},{"date":"2022-10-28","current":-45.703167,"twenty":-33.862283,"median":-1.627879,"eighty":-1.347563,"marketCap":12532153356},{"date":"2022-11-04","current":-47.889579,"twenty":-34.244719,"median":-1.690075,"eighty":-1.349418,"marketCap":13259465828},{"date":"2022-11-11","current":-54.075845,"twenty":-34.994866,"median":-1.704847,"eighty":-1.350052,"marketCap":15105720564},{"date":"2022-11-18","current":-54.261734,"twenty":-35.196512,"median":-1.718951,"eighty":-1.350584,"marketCap":15105720564},{"date":"2022-11-25","current":-53.682782,"twenty":-35.619635,"median":-1.724238,"eighty":-1.351761,"marketCap":14825984998},{"date":"2022-12-02","current":-48.838994,"twenty":-36.03292,"median":-1.732597,"eighty":-1.35394,"marketCap":13721029512},{"date":"2022-12-09","current":-49.869326,"twenty":-36.422906,"median":-1.741392,"eighty":-1.358753,"marketCap":14140632861},{"date":"2022-12-16","current":-49.68927,"twenty":-37.110092,"median":-1.751441,"eighty":-1.359673,"marketCap":14056712191},{"date":"2022-12-23","current":-50.662334,"twenty":-37.815892,"median":-1.768923,"eighty":-1.360488,"marketCap":14336447757},{"date":"2022-12-30","current":-49.810048,"twenty":-38.311423,"median":-1.779108,"eighty":-1.360805,"marketCap":14266513866},{"date":"2023-01-06","current":-59.889287,"twenty":-40.721309,"median":-1.788803,"eighty":-1.363025,"marketCap":17329618313},{"date":"2023-01-13","current":-63.745527,"twenty":-45.866985,"median":-1.802005,"eighty":-1.36768,"marketCap":18798230035},{"date":"2023-01-20","current":-63.149098,"twenty":-47.156842,"median":-1.813375,"eighty":-1.37425,"marketCap":18462547356},{"date":"2023-01-27","current":-66.866956,"twenty":-47.387404,"median":-1.821995,"eighty":-1.377188,"marketCap":19553516063},{"date":"2023-02-03","current":-73.564914,"twenty":-48.362249,"median":-1.829186,"eighty":-1.383736,"marketCap":21623559251},{"date":"2023-02-10","current":-69.701176,"twenty":-48.844707,"median":-1.851102,"eighty":-1.384307,"marketCap":20364749204},{"date":"2023-02-17","current":-64.035674,"twenty":-49.537684,"median":-1.855758,"eighty":-1.3847,"marketCap":18532481247},{"date":"2023-02-24","current":-64.485757,"twenty":-50.027006,"median":-1.862627,"eighty":-1.384891,"marketCap":18434573799},{"date":"2023-03-03","current":-63.780925,"twenty":-50.485877,"median":-1.867346,"eighty":-1.38785,"marketCap":18350653129},{"date":"2023-03-10","current":-60.239244,"twenty":-61.173659,"median":-60.239244,"eighty":-59.240154,"marketCap":17203737309},{"date":"2023-03-17","current":-62.669341,"twenty":-47.542697,"median":-2.429029,"eighty":-1.48035,"marketCap":18070917563},{"date":"2023-03-24","current":-45.662533,"twenty":-47.984113,"median":-2.53136,"eighty":-1.481306,"marketCap":16196689271},{"date":"2023-03-31","current":-46.093483,"twenty":-47.542697,"median":-2.548374,"eighty":-1.490337,"marketCap":16224662828},{"date":"2023-04-06","current":-48.86677,"twenty":-47.716138,"median":-2.561601,"eighty":-1.495259,"marketCap":17189750530},{"date":"2023-04-14","current":-56.564392,"twenty":-48.662655,"median":-2.598807,"eighty":-1.500317,"marketCap":19917172299},{"date":"2023-04-21","current":-49.280859,"twenty":-49.129927,"median":-2.619059,"eighty":-1.504904,"marketCap":17343605092},{"date":"2023-04-28","current":-49.630581,"twenty":-49.425987,"median":-2.634146,"eighty":-1.508068,"marketCap":17336629125},{"date":"2023-05-05","current":-50.342119,"twenty":-49.440341,"median":-2.674332,"eighty":-1.510029,"marketCap":17614015191},{"date":"2023-05-12","current":-48.855125,"twenty":-49.440341,"median":-2.686457,"eighty":-1.516894,"marketCap":16976027239},{"date":"2023-05-19","current":-45.908385,"twenty":-49.440341,"median":-2.698506,"eighty":-1.517016,"marketCap":15727789942},{"date":"2023-05-25","current":-41.54518,"twenty":-49.382925,"median":-2.701078,"eighty":-1.526538,"marketCap":14174427972},{"date":"2023-06-02","current":-34.793168,"twenty":-49.298401,"median":-2.739146,"eighty":-1.532109,"marketCap":11830515714},{"date":"2023-06-09","current":-34.925134,"twenty":-49.235615,"median":-2.759506,"eighty":-1.534498,"marketCap":11858254321},{"date":"2023-06-16","current":-37.186478,"twenty":-49.201434,"median":-2.826735,"eighty":-1.535115,"marketCap":12565588789},{"date":"2023-06-23","current":-33.387247,"twenty":-49.125677,"median":-2.870574,"eighty":-1.537968,"marketCap":11220266369},{"date":"2023-06-30","current":-34.066835,"twenty":-49.004597,"median":-3.090995,"eighty":-1.544787,"marketCap":11345090099},{"date":"2023-07-07","current":-36.762281,"twenty":-48.902064,"median":-14.267689,"eighty":-1.550569,"marketCap":12218856207},{"date":"2023-07-14","current":-41.356214,"twenty":-48.859783,"median":-14.703758,"eighty":-1.557189,"marketCap":13938649816},{"date":"2023-07-21","current":-40.557094,"twenty":-48.855125,"median":-14.786695,"eighty":-1.590509,"marketCap":13605786537},{"date":"2023-07-28","current":-46.353331,"twenty":-48.848874,"median":-15.757242,"eighty":-1.616876,"marketCap":15533619696},{"date":"2023-08-04","current":-44.08654,"twenty":-48.841279,"median":-17.264004,"eighty":-1.625174,"marketCap":14798546621},{"date":"2023-08-11","current":-38.18706,"twenty":-48.770107,"median":-17.618697,"eighty":-1.639596,"marketCap":12745889732},{"date":"2023-08-18","current":-38.922819,"twenty":-48.618507,"median":-17.716316,"eighty":-1.669551,"marketCap":12898452069},{"date":"2023-08-25","current":-48.345542,"twenty":-48.469149,"median":-17.907229,"eighty":-1.691227,"marketCap":13869303300},{"date":"2023-09-01","current":-51.3714,"twenty":-48.848874,"median":-18.444474,"eighty":-1.700493,"marketCap":14798546621},{"date":"2023-09-08","current":-48.329437,"twenty":-48.855125,"median":-18.677203,"eighty":-1.704347,"marketCap":13758348873},{"date":"2023-09-15","current":-51.293354,"twenty":-49.02254,"median":-18.720104,"eighty":-1.706265,"marketCap":14715330801},{"date":"2023-09-22","current":-50.71226,"twenty":-49.227359,"median":-18.776742,"eighty":-1.712712,"marketCap":14485012880},{"date":"2023-09-29","current":-48.256147,"twenty":-49.384925,"median":-19.044047,"eighty":-1.719465,"marketCap":13807108743},{"date":"2023-10-06","current":-46.827986,"twenty":-49.333486,"median":-19.160007,"eighty":-1.722365,"marketCap":13392065394},{"date":"2023-10-13","current":-53.002537,"twenty":-49.510593,"median":-19.227015,"eighty":-1.723874,"marketCap":15135247460},{"date":"2023-10-20","current":-51.191925,"twenty":-49.7053,"median":-19.366357,"eighty":-1.725957,"marketCap":14595691106},{"date":"2023-10-27","current":-52.864392,"twenty":-49.863007,"median":-31.983773,"eighty":-1.729115,"marketCap":15066073568},{"date":"2023-11-03","current":-56.307135,"twenty":-50.091166,"median":-32.891609,"eighty":-1.731896,"marketCap":16089847162},{"date":"2023-11-10","current":-54.236606,"twenty":-50.200713,"median":-33.482197,"eighty":-1.734635,"marketCap":15494951696},{"date":"2023-11-17","current":-51.160216,"twenty":-50.265993,"median":-33.665831,"eighty":-1.738771,"marketCap":14747873667},{"date":"2023-11-24","current":-51.266082,"twenty":-50.347216,"median":-33.802098,"eighty":-1.742964,"marketCap":14900056229},{"date":"2023-12-01","current":-52.950552,"twenty":-50.44545,"median":-33.886683,"eighty":-1.749419,"marketCap":15453447361},{"date":"2023-12-08","current":-48.929335,"twenty":-50.480077,"median":-34.087991,"eighty":-1.750633,"marketCap":14222152092},{"date":"2023-12-15","current":-49.026997,"twenty":-50.503058,"median":-34.145914,"eighty":-1.755554,"marketCap":14332830318},{"date":"2023-12-22","current":-43.424521,"twenty":-50.480077,"median":-34.299503,"eighty":-1.767076,"marketCap":12686491701},{"date":"2023-12-29","current":-46.255966,"twenty":-50.462677,"median":-34.430704,"eighty":-1.768461,"marketCap":13585752290},{"date":"2024-01-05","current":-39.184116,"twenty":-50.422595,"median":-34.599164,"eighty":-1.773184,"marketCap":11427526875},{"date":"2024-01-12","current":-39.6374,"twenty":-50.376313,"median":-34.80723,"eighty":-1.779725,"marketCap":11565874658},{"date":"2024-01-19","current":-30.196245,"twenty":-50.355049,"median":-34.821291,"eighty":-1.786008,"marketCap":8798918998},{"date":"2024-01-26","current":-31.934796,"twenty":-50.349608,"median":-34.671634,"eighty":-1.788854,"marketCap":9269301461},{"date":"2024-02-02","current":-28.825732,"twenty":-50.344667,"median":-34.430704,"eighty":-1.792603,"marketCap":8356206093},{"date":"2024-02-09","current":-29.254358,"twenty":-50.300879,"median":-34.217523,"eighty":-1.798947,"marketCap":8522223432},{"date":"2024-02-16","current":-30.719933,"twenty":-50.268713,"median":-34.145914,"eighty":-1.80168,"marketCap":8951101560},{"date":"2024-02-23","current":-31.264593,"twenty":-50.247304,"median":-34.087991,"eighty":-1.80225,"marketCap":9061779786},{"date":"2024-03-01","current":-32.723882,"twenty":-50.231028,"median":-34.066835,"eighty":-1.804417,"marketCap":9490657913},{"date":"2024-03-08","current":-29.180924,"twenty":-50.209139,"median":-33.882824,"eighty":-1.810355,"marketCap":8466884319},{"date":"2024-03-15","current":-38.27424,"twenty":-50.205712,"median":-33.955792,"eighty":-1.815595,"marketCap":11095492196},{"date":"2024-03-22","current":-31.908479,"twenty":-50.190664,"median":-34.067344,"eighty":-1.818584,"marketCap":9241631904},{"date":"2024-03-28","current":-24.103932,"twenty":-50.165789,"median":-33.921238,"eighty":-1.822598,"marketCap":9379979687},{"date":"2024-04-05","current":-21.238245,"twenty":-50.161899,"median":-33.878964,"eighty":-1.824885,"marketCap":8259362645},{"date":"2024-04-12","current":-23.110595,"twenty":-50.151875,"median":-33.802098,"eighty":-1.826503,"marketCap":8992605895},{"date":"2024-04-19","current":-19.536242,"twenty":-50.114215,"median":-33.665831,"eighty":-1.826965,"marketCap":7595293286},{"date":"2024-04-26","current":-24.86909,"twenty":-50.088677,"median":-33.524232,"eighty":-1.828404,"marketCap":9656675253},{"date":"2024-05-03","current":-25.37705,"twenty":-50.062515,"median":-33.352238,"eighty":-1.831056,"marketCap":9847104749},{"date":"2024-05-10","current":-28.766023,"twenty":-49.984649,"median":-32.891609,"eighty":-1.83471,"marketCap":11188634469},{"date":"2024-05-17","current":-26.814161,"twenty":-49.910756,"median":-32.645746,"eighty":-1.838991,"marketCap":10414143084},{"date":"2024-05-24","current":-24.37715,"twenty":-49.863007,"median":-32.538199,"eighty":-1.85106,"marketCap":9446028853},{"date":"2024-05-31","current":-22.961819,"twenty":-49.832194,"median":-31.995691,"eighty":-1.851562,"marketCap":8906650925},{"date":"2024-06-07","current":-23.597218,"twenty":-49.791236,"median":-31.831896,"eighty":-1.853648,"marketCap":9141764381},{"date":"2024-06-14","current":-25.2268,"twenty":-49.715987,"median":-31.583979,"eighty":-1.855758,"marketCap":9764123529},{"date":"2024-06-21","current":-24.778424,"twenty":-49.68927,"median":-31.264593,"eighty":-1.85665,"marketCap":9570500683},{"date":"2024-06-28","current":-24.179737,"twenty":-49.630581,"median":-31.20565,"eighty":-1.861612,"marketCap":9335387227},{"date":"2024-07-05","current":-24.256649,"twenty":-49.579614,"median":-31.075409,"eighty":-1.863236,"marketCap":9363047634},{"date":"2024-07-12","current":-24.614617,"twenty":-49.543522,"median":-30.719933,"eighty":-1.864248,"marketCap":9515179870},{"date":"2024-07-19","current":-22.932666,"twenty":-49.516711,"median":-30.371914,"eighty":-1.866757,"marketCap":8865160315},{"date":"2024-07-26","current":-21.849753,"twenty":-49.509718,"median":-30.196245,"eighty":-1.877125,"marketCap":8477914622},{"date":"2024-08-02","current":-23.039429,"twenty":-49.464314,"median":-29.432845,"eighty":-1.879923,"marketCap":8934311331},{"date":"2024-08-09","current":-23.843465,"twenty":-49.442887,"median":-29.180924,"eighty":-1.895372,"marketCap":9307726820},{"date":"2024-08-16","current":-22.559268,"twenty":-49.415633,"median":-28.9562,"eighty":-1.89943,"marketCap":8809839502},{"date":"2024-08-23","current":-22.852245,"twenty":-49.399666,"median":-28.825732,"eighty":-1.901269,"marketCap":8961971738},{"date":"2024-08-30","current":-11.943567,"twenty":-49.3743,"median":-28.234141,"eighty":-1.902953,"marketCap":9750293326},{"date":"2024-09-06","current":-12.49661,"twenty":-49.298401,"median":-27.689087,"eighty":-1.905899,"marketCap":10206690035},{"date":"2024-09-13","current":-13.497126,"twenty":-49.241725,"median":-26.979872,"eighty":-1.909574,"marketCap":10995011623},{"date":"2024-09-20","current":-13.062266,"twenty":-49.227359,"median":-26.322214,"eighty":-1.921267,"marketCap":10704577354},{"date":"2024-09-27","current":-13.171028,"twenty":-49.207151,"median":-25.785602,"eighty":-1.928589,"marketCap":10858622900},{"date":"2024-10-04","current":-15.027739,"twenty":-49.149023,"median":-25.671471,"eighty":-1.933191,"marketCap":12333080578},{"date":"2024-10-10","current":-14.207383,"twenty":-49.070792,"median":-25.307724,"eighty":-1.941223,"marketCap":11588961750},{"date":"2024-10-18","current":-15.069052,"twenty":-49.03582,"median":-25.061172,"eighty":-1.946379,"marketCap":12222840752},{"date":"2024-10-25","current":-15.256895,"twenty":-49.024041,"median":-24.869468,"eighty":-1.949107,"marketCap":12374420513},{"date":"2024-11-01","current":-14.822157,"twenty":-49.000774,"median":-24.786784,"eighty":-1.954883,"marketCap":12029921055},{"date":"2024-11-08","current":-15.294589,"twenty":-48.949872,"median":-24.715433,"eighty":-1.968234,"marketCap":12319300600},{"date":"2024-11-15","current":-13.566563,"twenty":-48.916822,"median":-24.654219,"eighty":-1.969012,"marketCap":10844842922},{"date":"2024-11-22","current":-13.177664,"twenty":-48.864441,"median":-24.330876,"eighty":-1.969169,"marketCap":10527903421},{"date":"2024-11-29","current":-13.236939,"twenty":-48.855125,"median":-24.220233,"eighty":-1.969308,"marketCap":10569243356},{"date":"2024-12-06","current":-14.115834,"twenty":-48.853041,"median":-24.165087,"eighty":-1.969669,"marketCap":11244462292},{"date":"2024-12-13","current":-13.124464,"twenty":-48.843564,"median":-24.032421,"eighty":-1.970751,"marketCap":10445223551},{"date":"2024-12-20","current":-11.351432,"twenty":-48.816032,"median":-23.851379,"eighty":-1.972463,"marketCap":8984545851},{"date":"2024-12-27","current":-10.332247,"twenty":-48.747145,"median":-23.809649,"eighty":-1.97553,"marketCap":8171527131},{"date":"2025-01-03","current":-10.113262,"twenty":-48.716497,"median":-23.739142,"eighty":-1.990149,"marketCap":8006167392},{"date":"2025-01-10","current":-9.732379,"twenty":-48.613383,"median":-23.61918,"eighty":-2.006193,"marketCap":7675447913},{"date":"2025-01-17","current":-10.230835,"twenty":-48.469149,"median":-23.55525,"eighty":-2.01137,"marketCap":8075067283},{"date":"2025-01-24","current":-10.514129,"twenty":-48.405254,"median":-23.47864,"eighty":-2.012282,"marketCap":8350666849},{"date":"2025-01-28","current":-10.183162,"twenty":-48.397728,"median":-23.40795,"eighty":-2.012658,"marketCap":8130187197},{"date":"2025-02-07","current":-10.970133,"twenty":-48.362249,"median":-23.267866,"eighty":-2.014049,"marketCap":8708946285},{"date":"2025-02-14","current":-12.104222,"twenty":-48.345542,"median":-23.110595,"eighty":-2.015243,"marketCap":9604644875},{"date":"2025-02-21","current":-12.995643,"twenty":-48.329437,"median":-23.048952,"eighty":-2.019542,"marketCap":10348763703},{"date":"2025-02-28","current":-12.239978,"twenty":-48.256147,"median":-22.974507,"eighty":-2.021009,"marketCap":9714884701},{"date":"2025-03-07","current":-12.692506,"twenty":-48.245005,"median":-22.928973,"eighty":-2.025061,"marketCap":10114504072},{"date":"2025-03-14","current":-12.203883,"twenty":-48.229099,"median":-22.907908,"eighty":-2.084234,"marketCap":9728664679},{"date":"2025-03-21","current":-13.211656,"twenty":-48.147823,"median":-22.839239,"eighty":-2.088441,"marketCap":10527903421},{"date":"2025-03-28","current":-22.490798,"twenty":-48.083454,"median":-22.765665,"eighty":-2.095427,"marketCap":12401980470},{"date":"2025-04-03","current":-24.037662,"twenty":-47.928354,"median":-22.787126,"eighty":-2.100685,"marketCap":13228779168}],"updateTime":1744005289517}}}